Haya Therapeutics

Haya Therapeutics is dedicated to advancing precision medicine by focusing on regulatory RNAs derived from the dark genome. The company's innovative approach aims to develop RNA-based therapies that can reprogram disease-driving cellular states, targeting conditions such as fibrotic diseases, cardiovascular issues, and metabolic disorders. Haya uses its proprietary technology to identify and manipulate long non-coding RNAs (lncRNAs) to prevent ...

Country

Switzerland

Website

hayatx.com

Founded

2019

Socials

Source of information:

hayatx.com

Add to My List

Key Executives

Samir Ounzain

CEO & Co-founder

Daniel Blessing

CTO & Co-founder

Industries

Biotech

Add Your Company

Disclaimer

The content of this website is not directed at or intended for persons in the United Kingdom or any other jurisdiction where the provision of the website or services would breach any applicable law or registration or would require any registration or license in any such jurisdiction. The content of this website should not be regarded as an invitation or inducement to engage in investment activity, to any person in the United Kingdom and investment opportunities described on this website are not intended to be acted upon by any persons in the United Kingdom.